NCT05070104: CPI-613 (Devimistat) in Combination With Modified FOLFIRINOX Plus Bevacizumab in Patients With Metastatic Colorectal Cancer |
|
|
| Withdrawn | 1 | 12 | NA | CPI-613, Devimistat, modified FFX, Bevacizumab | Cornerstone Pharmaceuticals | C04.588.274.476.411.307 | 03/24 | 11/24 | | |
NCT05325281: CPI-613 (Devimistat) in Combination With Chemoradiation in Patients With Pancreatic Adenocarcinoma |
|
|
| Recruiting | 1 | 24 | US | CPI-613® (Dose level -1.0 250 mg/m^2), Devimistat, alpha-lipoic acid analogue CPI-613, CPI-613® (Dose level 1.0 500 mg/m^2), CPI-613® (Dose level 2.0 1,000 mg/m^2), CPI-613® (Dose level 3.0 1,500 mg/m^2), CPI-613® Maximum Tolerated Dose (MTD), Gemcitabine, Gemzar®, Intensity-modulated Radiation Therapy | Medical College of Wisconsin, Cornerstone Pharmaceuticals, Barbara Ann Karmanos Cancer Institute | Pancreas Adenocarcinoma | 08/26 | 08/27 | | |
